Ovalalbumin, E.g., Avidin, Conalbumins, Etc. Patents (Class 530/367)
-
Publication number: 20120171240Abstract: The invention provides conjugates comprising an immune co-stimulatory polypeptide and an antigen or infectious agent. The conjugates are useful for generating or enhancing an immune response against the antigen or infectious agent. The invention also provides immune cells modified with a conjugate that are useful for generating or enhancing an immune response to an antigen or infectious agent. The invention also provides immunostimulatory moieties comprising an immune co-stimulatory polypeptide that are useful for stimulating an immune response. The invention also provides immunotherapy methods and methods of treating or preventing infections.Type: ApplicationFiled: September 7, 2011Publication date: July 5, 2012Inventors: Haval Shirwan, Kutlu G. Elpek, Esma S. Yolcu
-
Publication number: 20120164661Abstract: The present invention provides reagents containing binding moieties conjugated to dextran moieties, methods of making such reagents, and use of such reagents in a variety of molecular and cellular assays.Type: ApplicationFiled: September 22, 2011Publication date: June 28, 2012Applicant: BIOCEPT, INC.Inventors: Stephen D. MIKOLAJCZYK, Lisa S. MILLAR
-
Publication number: 20120164146Abstract: An isolated peptide of 12-20 amino acids in length comprising the amino acid sequence SEQ ID NO:1, wherein the serine residue (S) at position 8 of SEQ ID NO:1 is phosphorylated, is provided. Also provided is a human monophosphorylated alpha-enolase isoform wherein the serine residue (S) at position 419 of the human alpha-enolase amino acid sequence (SEQ ID NO:2) is phosphorylated and in which other post-translational modifications may be present. Further provided are antibodies capable of specifically binding the peptide and/or the isoform of the invention. The peptide, the isoform and the antibodies of the invention may be used in the diagnosis and/or amelioration and/or treatment of pancreatic adenocarcinoma.Type: ApplicationFiled: September 9, 2010Publication date: June 28, 2012Applicants: NATIMAB THERAPEUTICS S.R.L.Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello
-
Publication number: 20120156751Abstract: The synthesis of capped/tagged RNA, methods of use and kits providing same are contemplated. Tagged RNA permits isolation of RNA transcripts in vitro. The ability to isolate and purify capped RNA results in improved transcription and translation and provides a tool for identifying RNA-protein interactions. Such capped RNA finds use in therapeutic applications, diagnosis and prognosis and in the treatment of cancers and HIV.Type: ApplicationFiled: December 13, 2011Publication date: June 21, 2012Applicant: APPLIED BIOSYSTEMS, LLCInventors: Anilkumar Kore, Shanmugasundaram Muthian, Irudaya Charles
-
Publication number: 20120148490Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.Type: ApplicationFiled: December 1, 2011Publication date: June 14, 2012Inventors: Benjamin H. Dutzar, Brian R. Kovacevich, Patricia Dianne NcNeill, Danielle M. Mitchell, Ethan W. Ojala, Pei Fan, Jens Billgren, Erica A. Stewart, Corinne C. Akatsuka, Betty Yu-Ching Chang, John A. Latham, Leon F. Garcia-Martinez
-
Publication number: 20120141590Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.Type: ApplicationFiled: September 30, 2011Publication date: June 7, 2012Inventors: Michael Malakhov, Fang Fang
-
Publication number: 20120130050Abstract: This invention provides a biomolecule modifying substrate comprising biomolecules selectively fixed to given regions thereon. The biomolecule modifying substrate comprises: a substrate at least comprising a first surface and a second surface; a first linker molecule comprising a hydrocarbon chain and a functional group capable of selectively binding to the first surface at one end of the hydrocarbon chain, which is bound to the first surface via such functional group; a second linker molecule comprising a reactive group capable of binding to the hydrocarbon chain of the first linker molecule, which is bound to the first linker molecule via a bond between the reactive group and the hydrocarbon chain; and a biomolecule bound thereto via the second linker molecule.Type: ApplicationFiled: July 29, 2010Publication date: May 24, 2012Inventors: Yasuhiko Tada, Hiroshi Yoshida, Toshiro Saito, Masatoshi Narahara, Hiroaki Nakagawa
-
Publication number: 20120114699Abstract: Modified allergens having reduced allergenicity compared to corresponding native allergenic material, wherein all or a part of the primary amine groups of the lysine and arginine residues of the allergenic molecules are functionalized and the modified allergens have the structure wherein R and R2 are independently selected from H, C1-C5 alkyl, phenyl, phenyl substituted in ortho, meta, or para with a hydroxy, C1-C4 alkoxy, halogen, amino, alkylamino, dialkylamino, mercapto, C1-C4 alkylmercapto group; X represents O, S, or NR3, where R3 is H, alkyl with 1-6 carbon atoms, phenyl, or CN; R1 represents H, alkyl with 1-8 carbon atoms, phenyl or arylalkyl with up to 8 carbon atoms, or alkyl containing a heterocyclic ring; prot represents the protein residue of the allergen; n is the number of functionalized arginine groups and ranges between 1 and the number of arginine groups present in the allergen; m is the number of functionalized lysine groups and ranges between 1 and the number of lysine groups present inType: ApplicationFiled: October 2, 2009Publication date: May 10, 2012Applicant: LOFARMA S.P.A.Inventors: Giovanni Mistrello, Daniela Roncarolo, Dario Zanoni, Stefania Zanotta, Paolo Falagiani, Pietro Falagiani
-
Publication number: 20120095186Abstract: A polyion complex (PIC) or a PIC nanoparticle that may be easily prepared, and that is finally disappeared in vivo due to its suitable biodegradability while exhibiting high stability in vivo, an immunotherapy agent comprising the PIC nanoparticle to which various antigen proteins or peptides may be easily conjugated or incorporated and/or which may be easily mixed with the antigen proteins or peptides, as well as a process for preparing thereof are provided. Specifically, a polyion complex (PIC) comprising a hydrophobized poly(acidic amino acid) and a basic polypeptide, a nanoparticle thereof having a particle shape, an immunotherapy agent comprising the PIC nanoparticle, as well as a process for preparing the PIC, comprising steps of introducing a hydrophobic amino acid to a poly(acidic amino acid) to prepare a hydrophobized poly(acidic amino acid), and dissolving the hydrophobized poly(acidic amino acid) prepared to a buffer, and it is mixed with a basic polypeptide dissolved in a buffer.Type: ApplicationFiled: March 26, 2010Publication date: April 19, 2012Applicant: KAGOSHIMA UNIVERSITYInventors: Masanori Baba, Tomofumi Uto, Mitsuru Akashi, Takami Akagi, Chikateru Nozaki, Kazuyoshi Kaminaka
-
Publication number: 20120077284Abstract: Non-saturated or non-saturated and orientated binding surfaces for an affinity assay are provided, as are methods and compositions for their preparation. The non-saturated or non-saturated and orientated binding surfaces may further comprise paramagnetic microparticles. The methods include methods for making ligand::support coupler-based complexes by a process optionally employing a low input ratio of ligand to support coupler, by dilution, and by methods employing a dispersion and/or coating step using a block copolymer. Specific examples employing biotin-BSA and biotin-ovalbumin binding surfaces are provided, as well as strepavidin-coated microparticles and microparticles coated with capture moieties such as biotinylated immunoglobulins or fragments thereof. Other examples couple a ligand to the solid surface. Further provided are dispersed microparticles and methods for making them.Type: ApplicationFiled: September 23, 2011Publication date: March 29, 2012Inventors: Joshua C. Soldo, James L. Sackrison
-
Publication number: 20120071633Abstract: The present invention relates to a process for purification of a target molecule, comprising the steps: (a) contacting a target molecule, and a population of target binding polypeptides (TBP), in solution for a sufficient time to allow complex formation; and (b) isolating the target from the complex from (a) by subsequent purification steps, wherein (i) the target binding polypeptides have at least two binding functionalities; a first binding functionality towards the target and a second binding functionality towards a catching ligand comprised in a solid support; and (ii) the first binding functionality comprises at least two binding sites for the target, and the target comprises at least two binding sites for the TBP.Type: ApplicationFiled: May 4, 2010Publication date: March 22, 2012Applicant: NOVOZYMES A/SInventors: Jan Khyse-Andersen, Lars Winther
-
Publication number: 20120052087Abstract: An immunogenic composition comprising a siderophore covalently linked to a pharmaceutically acceptable carrier molecule wherein the antigenicity of the siderophore moiety is sufficient to stimulate an immuno-logic response to the siderophore when the composition is circulating in the bloodstream of a human or non-human animal and vaccine.Type: ApplicationFiled: April 20, 2010Publication date: March 1, 2012Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventor: Raymond J. Bergeron, JR.
-
Publication number: 20120040378Abstract: Carisoprodol is a centrally-acting prescription drug of known abuse. Upon ingestion it is rapidly metabolised to meprobamate, also a prescription drug with abuse potential. Current immunoassays are specific for carisoprodol and therefore have a short window of detection and, furthermore, are ineffective at detecting meprobamate. The current invention, underpinned by an antibody specific for meprobamate, overcomes these deficiencies.Type: ApplicationFiled: August 9, 2011Publication date: February 16, 2012Applicant: RANDOX LABORATORIES LIMITEDInventors: Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
-
Publication number: 20120035320Abstract: The present invention provides nucleic acid delivery polyplex complexes and anionic open polyplexes comprising a nucleic acid molecule reversibly bound to one or more of nucleic acid delivery polyplex complexes.Type: ApplicationFiled: April 4, 2011Publication date: February 9, 2012Applicant: University of Iowa Research FoundationInventors: Kevin G. Rice, Nicholas J. Baumhover, Christian A. Fernandez, Kevin Anderson, Mark D. Ericson, Jason T. Duskey, Koby Kizzire, Sanjib Khargharia, Samuel T. Crowley
-
Publication number: 20120021437Abstract: Tetranor-PGDM/tetranor-PGJM-specific antibodies, immunogens used to generate them, the processes of their manufacture, and their uses in assay kits for detecting and quantifying tetranor-PGDM and tetranor-PGJM in biological fluids for determining biosynthesis of PGD2 in a subject or patient.Type: ApplicationFiled: June 14, 2011Publication date: January 26, 2012Applicant: Cayman Chemical Company, IncorporatedInventors: Jeffrey K. Johnson, Kirk M. Maxey, Daniel J. Tew, Andriy M. Kornilov
-
Publication number: 20120009624Abstract: The invention relates to a protein particle comprising chimeric protein having an aggregating part capable of forming or aggregating into a substantially insoluble protein particle when expressed by a cell; and a functional part capable of binding to, or being bound by, a target compound. Affinity matrixes comprising the protein particle are also provided.Type: ApplicationFiled: December 3, 2007Publication date: January 12, 2012Inventors: Jens Sommer-Knudsen, Moreland D. Gibbs
-
Publication number: 20120009212Abstract: Templated conjugates created from naturally-occurring protein sequences found in pathogens, such as viruses, are disclosed. The sequences are “templated” into a consensus coiled-coil sequence in order to form a two-stranded antigen suitable for immunization of a subject.Type: ApplicationFiled: January 26, 2011Publication date: January 12, 2012Inventors: Robert S. HODGES, Kathryn V. Holmes, Zhe Yan, Wendy J. Hartsock, Zhaohui Qian, Brooke Elizabeth Bishop Hirsch
-
Publication number: 20120003674Abstract: The invention relates to an immunoassay method and kit for the indirect detection of chloral hydrate. The invention is underpinned by a novel immunogen that produces an antibody that is specific for the chloral hydrate metabolite trichloroethanol glucuronide. Detection and quantification of trichloroethanol glucuronide has important applications in clinical toxicology, drug facilitated crime, water testing and solvent exposure.Type: ApplicationFiled: June 29, 2011Publication date: January 5, 2012Applicant: Randox Laboratories LimitedInventors: Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
-
Publication number: 20110318381Abstract: The structural design, preparative methods and chemical composition of two structural formulations of bivalent vaccines against morphine-heroin addiction (morphine-6-hemisuccinyl-EDC-TFCS-tetanus toxoid and 3-O-carboxymethylmorphine-EDC-TFCS-tetanus toxoid), are disclosed. These vaccines are suitable for human use in which they are capable of triggering the synthesis of polyclonal antibodies against morphine opiate and its structural analogue, heroin, through the repeated in vivo administration of these formulations, in active vaccination protocols, in pre-clinical studies in rodents. The active vaccination paradigm through which these immunogens trigger a humoral immune response consolidated with a long-term immunological memory, characterized by the presence of high titers of specific antibodies against these two drugs of abuse, is also disclosed.Type: ApplicationFiled: July 14, 2011Publication date: December 29, 2011Applicant: Instituto Nacional De Psiquiatria Ramon De La Fuente MunizInventors: Benito Anton PALMA, Philippe Leff GELMAN
-
Publication number: 20110311990Abstract: Tetranor-PGEM/tetranor-PGAM-specific antibodies, immunogens used to generate them, the processes of their manufacture, and their uses for detecting and quantifying tetranor-PGEM in biological fluids for determining biosynthesis of PGE2 in a subject or patient.Type: ApplicationFiled: June 14, 2011Publication date: December 22, 2011Applicant: Cayman Chemical Company, IncorporatedInventors: Jeffrey K. Johnson, Kirk M. Maxey, Daniel J. Tew, Andriy M. Kornilov
-
Publication number: 20110305722Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.Type: ApplicationFiled: July 13, 2011Publication date: December 15, 2011Inventors: Wenbin MA, Benoit Van Den Eynde, Thierry Boon-Falleur, Catherine Germeau, Pierre Coulie
-
Publication number: 20110244545Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.Type: ApplicationFiled: May 2, 2011Publication date: October 6, 2011Inventors: Jerry W. Kosmeder, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
-
Publication number: 20110244544Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.Type: ApplicationFiled: May 2, 2011Publication date: October 6, 2011Inventors: Jerry W. Kosmeder, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
-
Publication number: 20110236952Abstract: The invention relates to compounds of formula (I?): in which A, L2, M and B are as defined in the description.Type: ApplicationFiled: September 22, 2009Publication date: September 29, 2011Applicant: CIS BIO InternationalInventors: Emmanuel Bourrier, Michel Laget, Laurent Lamarque, Norbet Tinel, Eric Trinquet, Hervé Bazin
-
Publication number: 20110171123Abstract: The present invention relates to a method for in vivo detection of a biofilm infection residing in a mammal, the method comprising (i) administering to the mammal a diagnostic-effective amount of a biofilm-specific probe, wherein the probe comprises a bio film-targeting moiety and a paramagnetic nanoparticle core; and (ii) imaging the mammal to detect the presence of the biofilm infection by observing the mammal using a magnetic resonance diagnostic technique after the biofilm-specific probe has been provided sufficient time to selectively bind to the bio film infection that may be present in the mammal. The invention also relates to methods of treatment of a bio film infection, and compositions and kits useful in the detection and/or treatment of bio film infections.Type: ApplicationFiled: September 2, 2009Publication date: July 14, 2011Applicant: University of Maryland, BaltimoreInventors: Mark E. Shirtliff, Rebecca A. Brady, Jeffrey G. Leid, Timothy L. Vail, Jennifer M. Kofonow
-
Publication number: 20110171678Abstract: Chemically reactive carbocyanine dyes incorporating an indolium ring moiety that is substituted at the 3-position by a reactive group or by a conjugated substance, and their uses, are described. Conjugation through this position results in spectral properties that are uniformly superior to those of conjugates of spectrally similar dyes wherein attachment is at a different position. The invention includes derivative compounds having one or more benzo nitrogens.Type: ApplicationFiled: October 18, 2010Publication date: July 14, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Wai-Yee Leung, Ching-Ying Cheung, Stephen Yue
-
Publication number: 20110165647Abstract: A nanoparticle conjugate comprising a nanoparticle having one or more peptide-ol compounds and one or more polyethylene glycol (PEG) compounds attached thereto. A method of producing the nanoparticle conjugate is also described.Type: ApplicationFiled: February 4, 2009Publication date: July 7, 2011Inventors: David G. Fernig, Laurence Duchesne
-
Publication number: 20110158906Abstract: The present invention provides a micelle comprising an amphiphilic block copolymer, said amphiphilic block copolymer consisting of (a) a hydrophobic polymer attached to the 5? end of a first nucleic acid molecule, wherein said first nucleic acid molecule is hybridized with a second nucleic acid molecule, wherein a targeting unit capable of selectively binding to a specific cell type and/or tissue is attached to the 5? end of said second nucleic acid molecule; and/or (b) a hydrophobic polymer attached to the 3? end of a first nucleic acid molecule, wherein said first nucleic acid molecule is hybridized with a second nucleic acid molecule, wherein a targeting unit capable of selectively binding to a specific cell type and/or tissue is attached to the 3? end of said second nucleic acid molecule.Type: ApplicationFiled: August 13, 2008Publication date: June 30, 2011Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.Inventors: Klaus Müllen, Fikri E. Alemdaroglu, Andreas Herrmann, N. Ceren Alemdaroglu, Peter Langguth
-
Publication number: 20110129413Abstract: Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.Type: ApplicationFiled: November 8, 2010Publication date: June 2, 2011Inventors: Thomas T. Morgan, Brian M. Barth, James H. Adair, Rahul Sharma, Mark Kester, Sriram S. Shanmugavelandy, Jill P. Smith, Erhan I. Altinoglu, Gail L. Matters, James M. Kaiser, Christopher McGovern
-
Publication number: 20110104103Abstract: The present invention relates to a cell-targeting complex comprising a targeting moiety and a deliverable compound, wherein said targeting moiety and said deliverable compound are joined by means of a (transition) metal ion complex having at least a first reactive moiety for forming a coordination bond with a reactive site of said targeting moiety and having at least a second reactive moiety for forming a coordination bond with a reactive site of said deliverable compound, and wherein said deliverable compound is a therapeutic compound.Type: ApplicationFiled: July 20, 2006Publication date: May 5, 2011Applicant: KREATECH BIOTECHNOLOGY B.V.Inventors: Robert Jochem Heetebrij, Robbert Jan Kok, Eduard Gerhard Talman, Klaas Poelstra, Grietje Molema
-
Publication number: 20110052507Abstract: The present invention relates to the use of a protein selected from one or more of casein, ovalbumin, whey protein and soy protein for combating (i.e. helping to prevent, inhibit and/or treat) dental erosion and/or tooth wear caused by subsequent exposure to acid.Type: ApplicationFiled: November 27, 2008Publication date: March 3, 2011Inventors: Michele Emily Barbour, Robert Peter Shellis
-
Publication number: 20100330111Abstract: The present invention relates to compounds consisting of glycolipids covalently bound to an antigen or a drug via a linker. The said compounds are able to induce a stronger immune response than a composition comprising separated glycolipids and antigen. The said compounds are also able to target drug to CD1d restricted cells.Type: ApplicationFiled: November 7, 2008Publication date: December 30, 2010Inventor: Vincent Serra
-
Publication number: 20100284909Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.Type: ApplicationFiled: May 5, 2010Publication date: November 11, 2010Applicant: NEW YORK UNIVERSITYInventors: Thomas M. Wisniewski, Fernando Goni
-
Publication number: 20100279432Abstract: Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided.Type: ApplicationFiled: July 8, 2010Publication date: November 4, 2010Applicant: ABBOTT LABORATORIESInventors: Anthony S. Muerhoff, Suresh M. Desai, Thomas P. Leary, George J. Dawson, Robin A. Gutierrez
-
Publication number: 20100273193Abstract: This disclosure is drawn to a triacetone triperoxide derivative in accordance with the general formula (I) and a diacetone diperoxide derivative in accordance with the general formula (II) wherein R1 is a hydrogen residue or an optionally halogenated or perhalogenated C1 to C5 alkyl group, R2 represents a linker molecule, and X represents a reactive or activatable group. A method for the preparation of the TATP or DADP derivatives and the use thereof as antigen for the preparation of TATP- or DADP-specific antibodies or other binders is also disclosed. The antibodies are preferably used in a biosensor for the detection of TATP or DADP in air.Type: ApplicationFiled: April 26, 2010Publication date: October 28, 2010Applicant: BAM Bundesanstalt fur Materialforschung und-pruefungInventors: Astrid Walter, Rudolf J. Schneider, Michael G. Weller
-
Publication number: 20100239497Abstract: The present invention describes chemically modified avidins that have higher permanence in treated tissues compared to wild type avidin. Avidin oxidation is performed by periodate incubation in the presence of the low affinity ligand HABA which, occupying the biotin binding sites, prevents protein denaturation during the oxidation step. Periodate oxidation generates CHO groups from avidin mannose ring opening that, once injected, react with tissue NH2 residues to form stable Schiff's bases. The anchored avidins maintain the ability to bind biotinylated agents endowed of therapeutic activity, like radiolabeled biotins, stem cells and somatic cells, useful for brachytherapies like Intraoperative Avidination Radionuclide Therapy (IART®) or degenerative or genetic diseases.Type: ApplicationFiled: July 16, 2008Publication date: September 23, 2010Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Rita DeSantis, Carlo Antonio Nuzzolo
-
Publication number: 20100191096Abstract: The present invention relates to complexes comprising one or more marker(s) and one or more biomolecules. The complexes according to the present invention have a variety of utilities, such as utility as a contrast agent in imaging methods, for example magnetic resonance imaging.Type: ApplicationFiled: June 6, 2008Publication date: July 29, 2010Inventor: Olav Tenstad
-
Publication number: 20100184184Abstract: Disclosed is a method for indirectly coupling a small molecule ligand to a molecule to be labelled with the ligand, the method comprising the step of: contacting a scaffold molecule, to which is attached at least one small molecule ligand, with the molecule to be labelled, the scaffold molecule having at least one group which is reactive towards a receiver moiety present or formed in situ on the molecule to be labelled, so as to forma bond between the scaffold molecule and the molecule to be labelled, thereby indirectly coupling the small molecule ligand to the molecule to be labelled.Type: ApplicationFiled: June 12, 2008Publication date: July 22, 2010Applicant: Innova Biosciences LimitedInventor: Nicholas Gee
-
Publication number: 20100184702Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: ApplicationFiled: December 18, 2009Publication date: July 22, 2010Inventors: Sally DeNardo, Gerald DeNardo, Rodney Balhorn
-
Publication number: 20100167333Abstract: The present invention provides a metal chelator and methods that facilitate binding, detecting, monitoring and quantitating of heavy metal ions in a sample.Type: ApplicationFiled: December 11, 2009Publication date: July 1, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Kyle R. Gee, Jolene Bradford, Vladimir V. Martin
-
Publication number: 20100075435Abstract: A means for conveniently and accurately measuring thyroxine or thyronine present in the blood or the like is provided: a compound represented by general formula (I) below: wherein L represents a linear or branched-chain linker having 5 to 50 total atoms; X represents one or more thyroxines, thyronines, or residues of derivatives thereof, bound to the main chain and/or side chain of the linker represented by L, a conjugate in the form of the above compound bonded to an avidin protein, and an aqueous dispersion including a microparticles the surface of which is modified with the above conjugate.Type: ApplicationFiled: July 27, 2009Publication date: March 25, 2010Inventors: Noriyuki KASAGI, Tadahiro Matsuno
-
Publication number: 20100029494Abstract: The invention relates to novel classes of nucleotides that can be used as substrates for enzymes, e.g. for labeling nucleic acids.Type: ApplicationFiled: November 5, 2004Publication date: February 4, 2010Inventors: Dmitry Cherkasov, Christian Hennig
-
Publication number: 20090136522Abstract: The present invention relates, in general, to HIV and, in particular, to immunogens that present epitopes located in the membrane external proximal region (MPER) of HIV-I envelope gp41 in multivalent form and to methods of using same.Type: ApplicationFiled: March 26, 2007Publication date: May 28, 2009Inventors: Barton F. Haynes, Michael Moody, Laurent Verkozcy, Bruce A. Sullenger, Juliana Layzer
-
Publication number: 20080306010Abstract: The present invention relates to a vaccine composition for the prevention and treatment of allergic disease comprising irradiated ovalbumin as an effective ingredient, more precisely a method for preparing an immunogen of a vaccine for the prevention and treatment of allergic disease using the irradiated ovalbumin which is separated and purified from the albumen of an egg, a vaccine composition for the prevention and treatment of allergic disease comprising the irradiated ovalbumin as an effective ingredient, and a method for the prevention and treatment of allergic disease using the vaccine comprising the irradiated ovalbumin. In the mouse vaccinated with the irradiated ovalbumin, humoral and cell mediated immune responses were both reduced, suggesting that allergic reaction was inhibited. Thus, the composition of the present invention can be effectively used as a vaccine for the prevention and treatment of allergic disease.Type: ApplicationFiled: September 11, 2007Publication date: December 11, 2008Applicant: KOREA ATOMIC ENERGY RESEARCH INSTITUTEInventors: Myung-Woo Byun, Ju-Woon Lee, Jae-Hun Kim, Jee-Hyun Seo
-
Patent number: 7446089Abstract: The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron stimulates surface motility in bacteria thus inhibiting the ability of a bacterial population to develop into a biofilm.Type: GrantFiled: October 4, 2004Date of Patent: November 4, 2008Inventors: Pradeep K. Singh, Michael J. Welsh, Everett P. Greenberg
-
Publication number: 20080107660Abstract: The invention relates to binding agents which can be induced to aggregate in response to a specific stimulus. In preferred embodiments the binding agents comprise at least a binding member for a binding partner and the binding partner. At least one of the binding member and binding partner are reversibly masked such that a plurality of binding agents are not able to aggregate with one another until the masked moiety is unmasked. Preferred mechanisms to induce aggregation include irradiation and enzyme action. Applications of the invention include signal amplification in biochemical assays and provision of high local concentrations of therapeutic agents in vivo.Type: ApplicationFiled: February 25, 2005Publication date: May 8, 2008Inventor: Colin Self
-
Patent number: 7229967Abstract: The compositions described herein comprise oxygenated albumin in an aqueous sterile physiological or serum solution. The albumin is oxygenated to increase the oxygen content up to O2 saturation with clinically useful oxygen gas. The preferred oxygen-saturated preparations, containing albumin in concentrations from about 5% w/v to about 25% w/v, are useful as clinical resuscitation preparations that release oxygen in a pattern similar to the release of oxygen by whole blood.Type: GrantFiled: November 12, 2004Date of Patent: June 12, 2007Assignee: Hunter Research CorporationInventor: Bernard V. Ecanow
-
Patent number: 7129210Abstract: A tissue adhesive sealant includes a cross-linkable protein in a solution that when combined with a cross-linking agent solution including an aldehyde and amino acid containing species reactive with the aldehyde cross-links to form a seal. The sealant is well suited for bonding tissue alone or in combination with a patch. The ratio between the aldehyde and the amino acid containing species is between 20:1 and 1:1 on an aldehyde moiety:amino acid or peptide subunit molar basis. Particularly strong seals are formed when the protein and cross-linking agent are present in a molar ratio of between 15:1 and 1:1.Type: GrantFiled: July 20, 2004Date of Patent: October 31, 2006Assignee: Covalent Medical, Inc.Inventors: Johan Lowinger, Bruno Lowinger, Frank DeLustro, David Cox, David A. Browdie
-
Patent number: 6620778Abstract: Described is a method for the preparation of a mixture of peptides having a cysteine content between 7-20 w/w % from a protein source, comprising cysteine containing proteins, comprising the steps of: a) cleaving the proteins of the protein source into peptides; b) digesting the peptides obtained in step a) by an exopeptidase, the action of which is at least attenuated at the position of a cysteine in the peptide, therewith forming digested peptides having a terminal cysteine; c) purifying the digested peptides, and the use of the preparation as active component in a medicament, especially for the treatment of conditions mediated by oxidative damage and for the elevation of cellular glutathion levels in the human or animal body.Type: GrantFiled: October 23, 2001Date of Patent: September 16, 2003Assignee: Campina Melkunie B.V.Inventors: Leon Franciscus Mallee, Ram Nimmagudda, Johannes Wilhelmus L. Boumans
-
Patent number: 6506570Abstract: A method of determining the gender of a bird in ovo comprises detecting the presence or absence of an elevated level of a sex-related hormone in the extra-embryonic fluid of the bird egg, and then determining the gender of the bird within the egg from the presence of an elevated level of a sex-related hormone therein. Preferably, the sex-related hormone is an estrogen. Further preferred are methods in which the extra-embryonic fluid is allantoic fluid. The method is preferably carried out on chicken eggs prior to or during transfer of the eggs from incubator to hatcher.Type: GrantFiled: March 23, 1999Date of Patent: January 14, 2003Assignee: Embrex, Inc.Inventor: Patricia V. Phelps